Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1941 1
1942 1
1946 1
1947 1
1950 1
1951 2
1952 3
1953 2
1954 1
1955 1
1956 2
1957 1
1959 4
1960 1
1961 3
1962 1
1963 1
1964 1
1966 2
1967 7
1968 4
1969 5
1970 1
1971 2
1972 7
1973 2
1974 3
1975 4
1976 7
1977 6
1978 1
1979 3
1980 5
1981 7
1982 2
1983 7
1984 4
1985 7
1986 7
1987 13
1988 7
1989 11
1990 10
1991 12
1992 8
1993 4
1994 6
1995 13
1996 15
1997 16
1998 14
1999 13
2000 11
2001 7
2002 16
2003 11
2004 9
2005 10
2006 15
2007 14
2008 21
2009 16
2010 18
2011 23
2012 17
2013 27
2014 24
2015 34
2016 34
2017 34
2018 31
2019 28
2020 33
2021 40
2022 26
2023 45
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

757 results

Results by year

Filters applied: . Clear all
Page 1
Atopic dermatitis.
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Weidinger S, et al. Among authors: irvine ad. Nat Rev Dis Primers. 2018 Jun 21;4(1):1. doi: 10.1038/s41572-018-0001-z. Nat Rev Dis Primers. 2018. PMID: 29930242 Review.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. Among authors: irvine ad. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Burmester GR, et al. Among authors: irvine ad. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735. RMD Open. 2023. PMID: 36754548 Free PMC article. Clinical Trial.
Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Canaud G, Lopez Gutierrez JC, Irvine AD, Vabres P, Hansford JR, Ankrah N, Branle F, Papadimitriou A, Ridolfi A, O'Connell P, Turner S, Adams DM. Canaud G, et al. Among authors: irvine ad. Genet Med. 2023 Dec;25(12):100969. doi: 10.1016/j.gim.2023.100969. Epub 2023 Aug 24. Genet Med. 2023. PMID: 37634128
The microbiome in patients with atopic dermatitis.
Paller AS, Kong HH, Seed P, Naik S, Scharschmidt TC, Gallo RL, Luger T, Irvine AD. Paller AS, et al. Among authors: irvine ad. J Allergy Clin Immunol. 2019 Jan;143(1):26-35. doi: 10.1016/j.jaci.2018.11.015. Epub 2018 Nov 23. J Allergy Clin Immunol. 2019. PMID: 30476499 Free PMC article. Review.
The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata.
Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, Bergfeld WF, Betz RC, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Donovan J, Eisman S, Farrant P, Green J, Grimalt R, Harries M, Hordinsky M, Irvine AD, Itami S, Jolliffe V, King B, Lee WS, McMichael A, Messenger A, Mirmirani P, Olsen E, Orlow SJ, Piraccini BM, Rakowska A, Reygagne P, Roberts JL, Rudnicka L, Shapiro J, Sharma P, Tosti A, Vogt A, Wade M, Yip L, Zlotogorski A, Sinclair R. Meah N, et al. Among authors: irvine ad. J Am Acad Dermatol. 2020 Jul;83(1):123-130. doi: 10.1016/j.jaad.2020.03.004. Epub 2020 Mar 9. J Am Acad Dermatol. 2020. PMID: 32165196
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation.
Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, Ruzek MC, Slivka PF, McGettrick AF, Banahan K, Hughes MM, Irvine AD, Fischer R, O'Neill LAJ. Hooftman A, et al. Among authors: irvine ad. Cell Metab. 2020 Sep 1;32(3):468-478.e7. doi: 10.1016/j.cmet.2020.07.016. Epub 2020 Aug 12. Cell Metab. 2020. PMID: 32791101 Free PMC article.
The role of Janus kinase signaling in the pathology of atopic dermatitis.
Guttman-Yassky E, Irvine AD, Brunner PM, Kim BS, Boguniewicz M, Parmentier J, Platt AM, Kabashima K. Guttman-Yassky E, et al. Among authors: irvine ad. J Allergy Clin Immunol. 2023 Dec;152(6):1394-1404. doi: 10.1016/j.jaci.2023.07.010. Epub 2023 Aug 1. J Allergy Clin Immunol. 2023. PMID: 37536511 Free article. Review.
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Paller AS, et al. Among authors: irvine ad. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391. JAMA Dermatol. 2023. PMID: 37043227 Free PMC article. Clinical Trial.
757 results